Veronique Lecault is COO at AbCellera Biologics Inc. (ABCL). They have made 5 open-market trades across 1 company since 2020, most recently 2024-06-21.
CIK 0001834418
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $5.9M since 2020, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 2,123,456 | $26.3M |
Shares reported on the most recent Form 4, priced at the 2024-06-24 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | BUY | 2023-09-12 | 2023-09-14 | $5.19 | $208K | -11.5% | -19.4% | -5.1% |
| ABCL | BUY | 2022-05-16 | 2022-05-17 | $6.34 | $1.3M | -0.3% | +16.9% | +71.0% |
| ABCL | BUY | 2022-02-28 | 2022-03-01 | $8.66 | $4.0M | -17.6% | +3.7% | -18.9% |
| ABCL | SELL | 2021-06-09 | 2021-06-10 | $25.50 | $25.5M | -13.3% | -26.8% | -28.4% |
| ABCL | BUY | 2020-12-15 | 2020-12-17 | $20.00 | $460K | -16.5% | -0.2% | -26.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.